BSLN Stock Overview
Engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BSLN from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Basilea Pharmaceutica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 46.75 |
| 52 Week High | CHF 48.25 |
| 52 Week Low | CHF 34.55 |
| Beta | 0.68 |
| 1 Month Change | 15.72% |
| 3 Month Change | 16.01% |
| 1 Year Change | 29.68% |
| 3 Year Change | 25.54% |
| 5 Year Change | 22.57% |
| Change since IPO | -53.71% |
Recent News & Updates
There May Be Underlying Issues With The Quality Of Basilea Pharmaceutica's (VTX:BSLN) Earnings
Feb 26
Basilea Pharmaceutica (VTX:BSLN) Could Easily Take On More Debt
Feb 20Recent updates
There May Be Underlying Issues With The Quality Of Basilea Pharmaceutica's (VTX:BSLN) Earnings
Feb 26Basilea Pharmaceutica (VTX:BSLN) Could Easily Take On More Debt
Feb 20Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now
Apr 18Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?
Sep 20Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)
Feb 17Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Jul 01Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long
Mar 24If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%
Feb 18Shareholder Returns
| BSLN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -1.4% | -4.4% | -2.0% |
| 1Y | 29.7% | 87.5% | 6.8% |
Return vs Industry: BSLN underperformed the Swiss Biotechs industry which returned 87.5% over the past year.
Return vs Market: BSLN exceeded the Swiss Market which returned 6.8% over the past year.
Price Volatility
| BSLN volatility | |
|---|---|
| BSLN Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 8.7% |
| 10% least volatile stocks in CH Market | 1.8% |
Stable Share Price: BSLN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: BSLN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 164 | David Veitch | www.basilea.com |
Basilea Pharmaceutica AG engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis. It also develops Fosmanogepix, an antifungal drug for the treatment of Candidemia, which is in Phase II clinical trials; BAL2062 for invasive mold infections, which is in Phase I of clinical trials; and BAL2420, an antibiotics to treat severe Enterobacteriaceae infections.
Basilea Pharmaceutica AG Fundamentals Summary
| BSLN fundamental statistics | |
|---|---|
| Market cap | CHF 567.68m |
| Earnings (TTM) | CHF 77.59m |
| Revenue (TTM) | CHF 208.54m |
7.3x
P/E Ratio2.7x
P/S RatioIs BSLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSLN income statement (TTM) | |
|---|---|
| Revenue | CHF 208.54m |
| Cost of Revenue | CHF 115.82m |
| Gross Profit | CHF 92.72m |
| Other Expenses | CHF 15.13m |
| Earnings | CHF 77.59m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.40 |
| Gross Margin | 44.46% |
| Net Profit Margin | 37.21% |
| Debt/Equity Ratio | 118.4% |
How did BSLN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/13 21:16 |
| End of Day Share Price | 2025/03/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Basilea Pharmaceutica AG is covered by 25 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Thomas Meyer | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |
| Markus Mayer | Baader Helvea Equity Research |